Loading filters...
50 results(scroll for more)
LocoregionalAdvanced (BCLC C)2026
Microbial metabolism dysfunction induced by transarterial chemoembolization aggravates postprocedural liver injury in HCC.
Li R et al. J Hepatol. 2026
LocoregionalAll Stages2026
Hepatocellular Carcinoma in Egypt in the Post HCV Elimination Era: Changing Aetiology, Surveillance, and Management Pathways.
El-Kassas M et al. Liver Int. 2026
LocoregionalAdvanced (BCLC C)2026
Radiological Loco-Regional Treatments for Cholangiocarcinoma: A Systematic Review of the Literature.
Pallas D et al. Liver Int. 2026
LocoregionalEarly (BCLC 0-A)2026
Galectin-1 modulates glycolysis through a GM1-galactose-dependent pathway to promote hyperthermia resistance in HCC.
Nguyen T et al. Hepatology. 2026
GeneralEarly (BCLC 0-A)2026
Impact of gut microbiota on hepatocellular carcinoma: Pathogenesis, diagnosis, prognosis, and therapeutic prospective.
Chen Q et al. Eur J Cancer. 2026
LocoregionalEarly (BCLC 0-A)2026
Elevation of Liver Elastic Value Following Radiofrequency Ablation Reflected Neutrophils Mediated Abscopal Effect in Liver Cancer.
Lin K et al. JHEP Rep. 2026
LocoregionalAll Stages2026
Irreversible Electroporation versus Stereotactic Body Radiotherapy for Solitary Hepatocellular Carcinoma ≤ 5 cm: A Multicenter Retrospective Study.
Xu M et al. JHEP Rep. 2026
TKIAll Stages2026
Lactylation Converts ABHD6 into a Mitochondrial Regulator that Drives Lenvatinib Resistance in Hepatocellular Carcinoma.
Sun Y et al. Cancer Res. 2026
ImmunotherapyAll Stages2026
Phase II trial with nivolumab and sorafenib in HCC identified enrichment of immunosuppressive monocytes in patients with Child-Pugh B liver dysfunction.
Keenan BP et al. JHEP Rep. 2026
ImmunotherapyAdvanced (BCLC C)2026
Comparing of Efficacy and Safety Between Sintilimab Plus IBI305 and PD-1 Inhibitor Plus TKIs in Combination of TACE for uHCC.
Ya H et al. Liver Int. 2026
ImmunotherapyAdvanced (BCLC C)2026
Reproducible safety and efficacy of durvalumab with or without tremelimumab for hepatocellular carcinoma in clinical practice: Results of the DT-real study.
Celsa C et al. JHEP Rep. 2026
LocoregionalAdvanced (BCLC C)2026
BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update.
Reig M et al. J Hepatol. 2026
ImmunotherapyAdvanced (BCLC C)2026
Plasma GPC3 reflects tumor GPC3 expression and predicts clinical outcomes in advanced HCC treated with atezolizumab + bevacizumab.
Shin DJ et al. JHEP Rep. 2026
ImmunotherapyAll Stages2026
Efficacy of liver transplantation after response to atezolizumab-bevacizumab downstaging of intermediate and advanced hepatocellular carcinoma (ImmunoXXL).
Bhoori S et al. J Hepatol. 2026
LocoregionalAdvanced (BCLC C)2026
Transarterial Chemoembolization Combined With Camrelizumab and Rivoceranib for Unresectable Hepatocellular Carcinoma (CHANCE2005/CARES-005): A Randomized Phase II Trial.
Zhu HD et al. J Clin Oncol. 2026
LocoregionalAdvanced (BCLC C)2026
Yttrium-90 radioembolization is associated with a lower risk of liver transplant waitlist dropout than chemoembolization in hepatocellular carcinoma.
Kim NG et al. J Hepatol. 2026
LocoregionalAll Stages2026
Biologically explicable multimodal model predicting local tumor progression and tumor invasiveness of hepatocellular carcinoma.
Ding W et al. Hepatology. 2026
LocoregionalAll Stages2026
MRI-Based Score to Predict Retreatment Response for Viable Hepatocellular Carcinomas After Transarterial Chemoembolization.
Wang W et al. Liver Int. 2026
ImmunotherapyAll Stages2026
Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma.
Yopp A et al. J Hepatol. 2026
ImmunotherapyAdvanced (BCLC C)2026
Outcomes of Nivolumab Plus Ipilimumab After Atezolizumab Plus Bevacizumab in Advanced HCC: An International Multicentre Study.
Kim JS et al. Liver Int. 2026
ImmunotherapyAdvanced (BCLC C)2026
NRF2-COX2-PGE 2 axis drives immune cold tumors and predicts resistance to combination immunotherapy in hepatocellular carcinoma.
Yamamoto S et al. Hepatology. 2026
GeneralEarly (BCLC 0-A)2026
Intratumoral Lactobacillus johnsonii Enhances Sensitivity to PD-1 Blockade by Inducing CD8+ T Cell Expansion in Hepatocellular Carcinoma.
Liu Q et al. Cancer Res. 2026
LocoregionalEarly (BCLC 0-A)2025
The Risk of Decompensation in Steatotic Liver Disease-Related Hepatocellular Carcinoma: A Comparison with Viral-Controlled Cases.
Matsushita Y et al. Liver Cancer. 2025
LocoregionalAdvanced (BCLC C)2025
Atezolizumab Plus Bevacizumab for TACE-Unsuitable Intermediate-Stage HCC Beyond Up-To-7 Criteria: Final Analysis of REPLACEMENT.
Ueshima K et al. Liver Int. 2025
LocoregionalEarly (BCLC 0-A)2025
Attenuation of the second peak of bimodal recurrence of HBV-related HCC after curative treatment in the antiviral era.
Chan LL et al. J Hepatol. 2025
LocoregionalAll Stages2025
Diagnosis and Treatment Response Monitoring of Liver Cancer Using Glypican-3-Targeted Single-Domain Antibody PET.
Fayn S et al. Clin Cancer Res. 2025
LocoregionalAll Stages2025
Targeting mTORC2-dependent AKT/FOXO1/RNF125 signaling exploits a therapeutic vulnerability in c-MET-activated and β-catenin-mutated hepatocellular carcinoma.
Wang X et al. Hepatology. 2025
LocoregionalAdvanced (BCLC C)2025
Immunologic effects of locoregional therapies for unresectable hepatocellular carcinoma.
Schmidt R et al. JHEP Rep. 2025
LocoregionalAll Stages2025
Long-Chain Fatty Acid Redistribution Induced by SLC27A2 Deficiency Facilitates Hypoxic Adaptation and Immunosuppression in Hepatocellular Carcinoma.
Fu C et al. Cancer Res. 2025
LocoregionalAdvanced (BCLC C)2025
Mevalonate pathway promotes liver cancer by suppressing ferroptosis through CoQ10 production and selenocysteine-tRNA modification.
Chen Y et al. J Hepatol. 2025
LocoregionalAdvanced (BCLC C)2025
Hepatocellular carcinoma with macrovascular invasion: Review and survival meta-analysis of initial local therapy using minimal prognostic criteria.
Fortuny M et al. Hepatology. 2025
LocoregionalAdvanced (BCLC C)2025
Atezolizumab plus Bevacizumab with Transcatheter Arterial Chemoembolization (Sandwich Strategy) versus Atezolizumab plus Bevacizumab Alone in Hepatocellular Carcinoma: A Multicenter Retrospective Study.
Hashimoto K et al. Liver Cancer. 2025
LocoregionalAdvanced (BCLC C)2025
No More Detours: Hepatopulmonary Shunt Reduction in a Patient with Hepatocellular Carcinoma after Treatment with Bevacizumab.
Jeschke M et al. Liver Cancer. 2025
LocoregionalEarly (BCLC 0-A)2026
Integrating multiphase MRI surrogates to improve microvascular invasion detection and recurrence risk stratification in HCC.
Li F et al. JHEP Rep. 2026
LocoregionalAll Stages2025
Patterns and Prognostic Stratification of Recurrence after Thermal Ablation in Patients with Hepatocellular Carcinoma.
Tan CP et al. Liver Cancer. 2025
LocoregionalAdvanced (BCLC C)2025
Change in Liver Function after Selective Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: JIVROSG-2001 PRESIDENT-ALBI - A Secondary Analysis of a Multicenter Randomized Controlled Trial.
Kodama Y et al. Liver Cancer. 2025
LocoregionalAdvanced (BCLC C)2025
Decoding tumor heterogeneity with imaging biomarkers predicts response to TACE plus immunotherapy and targeted therapy in HCC (CHANCE2204).
Jin ZC et al. Hepatology. 2025
TKIAdvanced (BCLC C)2025
Multicenter Phase 2 Trial of Second-Line Regorafenib in Patients with Unresectable Hepatocellular Carcinoma after Progression on Atezolizumab plus Bevacizumab.
Cheon J et al. Liver Cancer. 2025
ImmunotherapyAdvanced (BCLC C)2025
Early CTLA4 increase in CD45+ blood cells: an emerging biomarker of atezolizumab-bevacizumab resistance and worse survival in advanced hepatocarcinoma.
Gramantieri L et al. ESMO Open. 2025
TKIAll Stages2025
RIOK1 phase separation restricts PTEN translation via stress granules activating tumor growth in hepatocellular carcinoma.
Meng F et al. Nat Cancer. 2025
ImmunotherapyAdvanced (BCLC C)2025
Alpha-Fetoprotein and Des-Gamma-Carboxy Prothrombin-Based Tumor Marker Score for First-Line Immunotherapy Selection in Hepatocellular Carcinoma.
Tanaka K et al. Liver Cancer. 2025
ImmunotherapyAdvanced (BCLC C)2025
Efficacy of atezolizumab plus bevacizumab for unresectable HCC: Systematic review and meta-analysis of real-world evidence.
Manfredi GF et al. JHEP Rep. 2025
ImmunotherapyAdvanced (BCLC C)2025
Etiology of Hepatocellular Carcinoma May Influence the Pattern of Progression under Atezolizumab-Bevacizumab.
Stefanini B et al. Liver Cancer. 2025
ImmunotherapyAdvanced (BCLC C)2025
Cardiological adverse events in hepatocellular carcinoma patients receiving immunotherapy: Influence of comorbidities and clinical outcomes.
Fortuny M et al. Eur J Cancer. 2025
ImmunotherapyAdvanced (BCLC C)2025
Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b-2, study.
Finn RS et al. Lancet Oncol. 2025
TKIAdvanced (BCLC C)2026
Multicenter single-arm phase II trial of lenvatinib in patients with advanced hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab.
Kim HD et al. J Hepatol. 2026
TKIAdvanced (BCLC C)2025
Transarterial Chemoembolization plus Sorafenib versus Sorafenib Alone in Advanced Hepatocellular Carcinoma (SELECT): A Multicenter, Phase 3, Randomized, Controlled Trial.
Zhao Y et al. Liver Cancer. 2025
TKIAll Stages2025
Salsalate improves the anti-tumor efficacy of lenvatinib in MASH-driven hepatocellular carcinoma.
Tsakiridis EE et al. JHEP Rep. 2025
LocoregionalEarly (BCLC 0-A)2026
Ultra-selective radiation segmentectomy for early-stage hepatocellular carcinoma.
Malone CD et al. JHEP Rep. 2026
ImmunotherapyAdvanced (BCLC C)2025
Clinical Impact of Serum CRP Levels on Advanced HCC Treated With Durvalumab and Tremelimumab: A Multicentre Study.
Hatanaka T et al. Liver Int. 2025